Live feed
·
PRReleasevia Quantisnow
Eyegate Pharmaceuticals, Inc. logo

EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

ByQuantisnow·Wall Street's wire, on your screen.
EYEG· Eyegate Pharmaceuticals, Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EYEG (Eyegate Pharmaceuticals, Inc.) and more on Quantisnow.